

AD _____

Award Number: DAMD17-02-1-0725

TITLE: Structure-Based Design of CDK4-Specific Inhibitors

PRINCIPAL INVESTIGATOR: Ronen Marmorstein, Ph.D.

CONTRACTING ORGANIZATION: The Wistar Institute
Philadelphia, PA 19104

REPORT DATE: October 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050603 106

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 2004	3. REPORT TYPE AND DATES COVERED Annual (30 Sep 2003 - 29 Sep 2004)	
4. TITLE AND SUBTITLE Structure-Based Design of CDK4-Specific Inhibitors			5. FUNDING NUMBERS DAMD17-02-1-0725	
6. AUTHOR(S) Ronen Marmorstein, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Wistar Institute Philadelphia, PA 19104 E-Mail: Marmor@wistar.upenn.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) The inability to inhibit the activity of CDK4/6 kinase is implicated in a significant number of breast cancers, making it an ideal molecule for targeted inhibition. We propose to prepare CDK4/6-specific inhibitors that are based on the naturally occurring CDK4/6 specific inhibitory protein. p18 ^{INK4c} . Towards this goal, we have used structure-based-design to successfully prepare three mutant p18 ^{INK4c} proteins, F71N, F82Q and F92N, with increased stability. Significantly, the F71N mutant also shows enhanced CDK6 interaction and cell cycle inhibitory activity <i>in vivo</i> . We are currently preparing other mutations at positions 71, 82 and 92 of p18 ^{INK4c} to generate even more potent CDK4/6 inhibitors. Once this analysis is complete we will combine favorable mutants to create a "super stable" p18 ^{INK4c} protein that will be used as a scaffold to prepare small peptides derived from the optimally modified p18 ^{INK4c} protein. The preparation of this initial peptide will then lead to a set of lead peptides or non-peptidic compounds that can be further developed using combinatorial chemistry approaches. High affinity compounds developed through this approach can then be tested in cell culture systems and ultimately through clinical trials to treat CDK4/6-mediated breast cancers.				
14. SUBJECT TERMS breast cancer			15. NUMBER OF PAGES 8	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	5
Reportable Outcomes.....	6
Conclusions.....	6
References.....	6
Appendices.....	8

(5) INTRODUCTION

Distinct cancer types have been correlated with several proteins that are involved in the G1 to S transition of the mammalian cell cycle (Funk, 1999; Molinari, 2000). In particular, the inability to inhibit the activity of the paralogs cyclin-dependent kinases 4 and 6 (CDK4/6) are implicated in more than 80% of human neoplasias (Ortega et al., 2002). For example, the gene encoding the CDK4/6 inhibitory protein, p16^{INK4}, is deleted or mutated in the majority of leukemias, bladder cancers and familial melanomas (Roussel, 1999). The CDK4/6 stimulatory subunit, cyclin D1, is commonly found to be overexpressed or gene amplified in spontaneous breast cancers (Donnellan and Chetty, 1998; Khoo et al., 2002), and overexpression of cyclin D1 in mice leads to death due to breast cancer (Wang et al., 1994). Finally, CDK4 itself is overexpressed or gene amplified in about one third of breast cancers (Ortega et al., 2002). Together, these observations indicate that deregulation of the G1 to S transition of the mammalian cell cycle is tightly linked to the onset of several different cancer types, and that the CDK4/6 protein, in particular, is an excellent candidate for targeted inhibition for the treatment of breast cancer.

The vast majority of currently available CDK4/6 inhibitors have structural similarity to the common kinase cofactor ATP and, as a result of this, a major obstacle in developing these inhibitors into clinically useful drugs is overcoming harmful side effects due to a lack of CDK4/6 specificity (Toogood, 2001). Here, we propose to prepare a CDK4/6-specific kinase inhibitor that is based on the naturally occurring CDK4/6 specific inhibitory proteins of the INK4 family (Carnero and Hannon, 1998). We have previously determined the structure of the INK4 protein p18^{INK4c} revealing 5 contiguous ankyrin-like repeats (Venkataramani et al., 1998), and the structure of CDK6 in complex with p18^{INK4c} (Jeffrey et al., 2000) reveals that repeats 2 and 3 mediate most of the inhibitory interactions with CDK6. Based on these results, we hypothesize that a modified and truncated p18^{INK4c} protein (INK4-mod₂₋₃) can be prepared harboring only ankyrin-like repeats 2 and 3 in addition to amino acid substitutions that enhance the proteins CDK4/6 inhibitory activity. Modifications in p18^{INK4c} will include amino acid substitutions that increase the stability of the inhibitory domain in order to raise the likelihood of autonomous folding, and to increase the affinity of p18^{INK4c} for CDK4/6. INK4-mod₂₋₃ will then serve as a potent CDK4/6-specific peptide inhibitor itself as well as an excellent scaffold for the design of even smaller peptide or small molecule non-peptidic mimics that may have clinical application for the specific inhibition of CDK4/6 for the treatment of breast cancer.

The Specific Aims of the proposal are to (1) Prepare and characterize site-directed mutants of p18^{INK4c} with increased protein thermostability, association with CDK4/6, and cell-cycle inhibitory activity *in vivo*, (2) Prepare an autonomous ankyrin-like region 2-3 peptide derived from the optimally modified p18^{INK4c} (INK4-mod₂₋₃) protein prepared in aim 1, (3) Determine the X-ray crystal structure of INK4-mod₂₋₃ in complex with CDK6, and (4) Use the structural information from the CDK6/ INK4-mod₂₋₃ complex to initiate the structure-based design of peptide or small molecule non-peptidic mimics of INK4-mod₂₋₃.

(6) BODY

During the first year of the funding period we completed most of Aim1 (Tasks 1-3) to prepare and characterize site directed mutants of p18^{INK4c} with increased protein thermostability, association with CDK4/6 and cell-cycle inhibitory activity *in vivo* (Venkataramani et al., 2002). Specifically, we used a combination of structure-based mutagenesis, structural studies, and *in vitro* and *in vivo* studies to identify three p18^{INK4c} mutant proteins with increased protein thermostability and CDK4/6 inhibitor activity, F71N, F82Q and F92N. Of these three p18^{INK4c} mutant proteins the F71N mutant showed the most significant enhancement in protein stability and CDK4/6 inhibitory activity.

An assumption of the studies with p18^{INK4c} was that the mutations that stabilize this member of the INK4 proteins would also stabilize the p16^{INK4a} protein, thereby allowing us to use p18^{INK4c} as a suitable model system for designing small p16^{INK4a} mimics for CDK4/6 inhibition. Before moving forward with our studies we tested our assumption by preparing p16^{INK4a} mutations that correspond to the F71N, F82Q and F92N mutations prepared for p18^{INK4c}. Therefore, we prepared the p16^{INK4a} mutant proteins T79Q, T79N, F90N and A100N. Each of these mutant proteins were prepared by site-directed mutagenesis, and the proteins overexpressed in bacteria as inclusion bodies. The proteins were then solubilized by suspending them in 6M urea and refolded them by dialysis against a buffer in the absence of urea. Each of the soluble and refolded proteins was chromatographed on gel filtration using a Superdex-75 column. A summary of the gel filtration chromatographs and SDS-PAGE analysis of the mutant p16^{INK4a} proteins is summarized in figure 1 (appendix). Surprisingly, we found that while the majority of the native p16^{INK4a} protein chromatographs as a monomeric protein, each of the mutants show a large percentage of protein in the aggregated form (in the void volume of the column), suggesting that each of the p16^{INK4a} mutants that we prepared are less stable than the native protein. Crystallization trials with each of these p16^{INK4a} mutant proteins were also unsuccessful. We conclude from these studies that p18^{INK4c} may not serve as a suitable model for designing more thermostable p16^{INK4a} proteins. In light of this, we have now modified our Aims to directly study site-directed mutations and protein truncations in p16^{INK4a}, rather than p18^{INK4c}.

While we were designing stabilizing mutations in p16^{INK4a}, we noted a manuscript published by Peng and colleagues in which the authors used several complementary techniques to identify three stabilizing mutations in p16^{INK4a} (Cammatt et al., 2003). These mutations are W15D, L37S and L121R. Interestingly a combination of these stabilizing mutations (called HTM for hyperstable triple mutant) has an additive thermostability with the HTM mutant being 1.4 kcal/mol more stable than the wild-type protein. In addition, the HTM p16^{INK4a} mutant was able to rescue the oncogenic R24P, P81L and V126D p16^{INK4a} mutants for CDK4 binding. We have decided to take advantage of these seminal findings by preparing the HTM p16^{INK4a} mutant protein for our studies.

Over the coming year we will (1) Prepare a recombinant form of the HTM p16^{INK4a} mutant, and (2) purify and crystallize the HTM p16^{INK4a} protein and determine its three dimensional structure. The HTM p16 structure will then serve as a structural scaffold for Aims 2 and 3 of this proposal.

(7) KEY RESEARCH ACCOMPLISHMENTS

- Prepared recombinant p16^{INK4a} mutant proteins (T79Q, T79N, F90N and A100N) that were predicted to have increased thermal stability.
- Characterized the gel filtration behavior of the p16^{INK4a} mutants described above leading to the conclusion that the INK4 protein p18^{INK4c} does not serve as a good model for designing more thermostable p16^{INK4a} proteins.

(8) REPORTABLE OUTCOMES

None

(9) CONCLUSIONS

During the first year of the funding period we have successfully completed tasks 1-3 of the proposal. Specifically, we have prepared p18^{INK4c} mutant proteins that harbor increased protein stability and CDK4/6 inhibitory activity. During the second year of the funding period we addressed whether the INK4 protein, p18^{INK4c}, serves as a good model system for understanding the structure and stability of p16^{INK4a} and discovered that it does not. In light of these findings and a recent report by Peng and colleagues describing the preparation of a more thermostable and active p16^{INK4a} protein (p16^{INK4a}-HTM), we have shifted our focus to p16^{INK4a}-HTM for our subsequent studies (Aims 2 and 3).

Since the hyperactivity of the CDK4/6 kinase is associated with a large number of cancers including a significant number of breast cancers, CDK4/6 is a highly relevant target for the development of inhibitory compounds that may provide effective therapeutics for the treatment of breast cancer. Unfortunately, the vast majority of currently available CDK4/6 inhibitors have structural similarity to the common kinase cofactor ATP and, as a result of this; a major obstacle in developing these inhibitors into clinically useful drugs is overcoming harmful side effects due to a lack of CDK4/6 specificity. Our use of the INK4 family as a scaffold will result in the preparation of peptide inhibitors of CDK4/6 with enhanced specificity. The preparation of these initial peptides will then lead to a set of lead peptides or non-peptidic compounds that can be further developed using combinatorial chemistry approaches (Beeley and Berger, 2000; Kirkpatrick et al., 1999; Leach et al., 2000; Roe et al., 1998). High affinity compounds developed through this approach can then be tested in cell culture systems and ultimately through clinical trials to treat CDK4/6-mediated breast cancers.

(10) REFERENCES

- Beeley, N., and Berger, A. (2000). A revolution in drug discovery. Combinatorial chemistry still needs logic to drive science forward. *BMJ* 321, 581-582.
- Cammett, T. J., Luo, L., and Peng, Z. Y. (2003). Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations. *J Mol Biol* 327, 285-297.
- Carnero, A., and Hannon, G. J. (1998). The INK4 family of CDK inhibitors. *Curr Top Microbiol Immunol* 227, 43-55.
- Donnellan, R., and Chetty, R. (1998). Cyclin D1 and human neoplasia. *Mol Pathol* 51, 1-7.
- Funk, J. O. (1999). Cancer cell cycle control. *Anticancer Res* 19, 4772-4780.
- Jeffrey, P. D., Tong, L., and Pavletich, N. P. (2000). Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. *Genes Dev* 14, 3115-3125.
- Khoo, M. L., Ezzat, S., Freeman, J. L., and Asa, S. L. (2002). Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. *Journal of Clinical Endocrinology & Metabolism* 87, 1810-1813.

- Kirkpatrick, D. L., Watson, S., and Ulhaq, S. (1999). Structure-based drug design: Combinatorial chemistry and molecular modeling. *Comb Chem High Throughput Screen* 2, 211-221.
- Leach, A. R., Bryce, R. A., and Robinson, A. J. (2000). Synergy between combinatorial chemistry and de novo design. *Journal of Molecular Graphics & Modelling* 18, 358-367.
- Molinari, M. (2000). Cell cycle checkpoints and their inactivation in human cancer [In Process Citation]. *Cell Prolif* 33, 261-274.
- Ortega, S., Malumbres, M., and Barbacid, M. (2002). Cyclin D-dependent kinases, INK4 inhibitors and cancer. *Biochimica et Biophysica Acta* 1602, 73-87.
- Roe, D. C., Kick, E. K., Skillman, A. G., Liu, G., and Ellman, J. A. (1998). Combining structure-based drug design with combinatorial chemistry. *Abstr Pap Am Chem Soc* 216, 011-COMP.
- Roussel, M. F. (1999). The INK4 family of cell cycle inhibitors in cancer. *Oncogene* 18, 5311-5317.
- Toogood, P. L. (2001). Cyclin-dependent kinase inhibitors for treating cancer. *Medicinal Research Reviews* 21, 487-498.
- Venkataramani, R., Swaminathan, K., and Marmorstein, R. (1998). Crystal structure of the CDK4/6 inhibitory protein p18^{INK4c} provides insights into ankyrin-like repeat structure and function and tumor-derived p16^{INK4} mutations. *Nature Struc Biol* 5, 74-81.
- Venkataramani, R. N., MacLachlan, T. K., Chai, X., El-Deiry, W. S., and Marmorstein, R. (2002). Structure-based design of p18INK4c proteins with increased thermodynamic stability and cell cycle inhibitory activity. *J Biol Chem* 277, 48827-48833.
- Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., and Schmidt, E. V. (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. *Nature* 369, 669-671.

(11) APPENDIX




Figure 1. (a) Overlay of gel filtration chromatograph of wild-type p16^{INK4} and several representative site-directed p16^{INK4} mutants (indicated on figure). (b) SDS-PAGE analysis of wild-type p16^{INK4} and the T79Q p16^{INK4} mutant.